Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma
Author:
Publisher
Springer International Publishing
Link
http://link.springer.com/content/pdf/10.1007/978-3-319-46029-1_61-1
Reference107 articles.
1. Ackerman A, Klein O, McDermott DF et al (2014) Outcomes of patients with metastatic melanoma treated with immuno-therapy prior to or after BRAF inhibitors. Cancer 120:1695–1701
2. Algazi A, Othus M, Daud A et al (2015) SWOG S1320: a randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAF V600E/k mutant melanoma. J Clin Oncol 33(Suppl):TPS9093
3. Ascierto PA, Simeone E, Giannarelli D et al (2012) Sequencing of BRAF inhibitors and ipilimumab in patients with meta-static melanoma: a possible algorithm for clinical use. J Transl Med 10:107
4. Ascierto PA, Simeone E, Grimaldi AM et al (2013) Do BRAF inhibitors select for populations with different disease progression kinetics? J Transl Med 11:61
5. Ascierto PA, Simeone E, Sileni VC et al (2014a) Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Investig 32:144–149
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies;Frontiers in Cell and Developmental Biology;2020-03-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3